Resources

Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included: targeted analyses on the ideal age group for iNGRVs and potential future combination vaccine options, impact and cost effectiveness analyses, a feasibility and acceptability study with national stakeholders and healthcare providers in six countries, and a demand forecast. This brief provides a comprehensive summary of the results.

Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included an impact and cost-effectiveness analysis examining multiple rotavirus vaccine options and strategies. This fact sheet provides an overview of the results.

This document, current as of May 25, 2022, provides data and information from PATH's modeling focused on the global supply and demand of autodisable (AD) syringes, which are used for COVID-19 and routine immunizations in more than 100 countries. The current forecast indicates that, despite an estimated gap of 360 million AD syringes in Q 1 2022, production capacity is adequate to meet syringe demand in Q2 2022 through Q3 2023, due to the significant capacity expansions undertaken by manufacturers and slower COVID-19 vaccination uptake than targeted timelines in many countries. The AD syringe gap analysis combines maximum syringe supply capacity collected from manufacturers in Q2 2022 with estimated syringe demand from all countries known to use AD syringes globally, including demand for both COVID- 19 and non-COVID-19 immunizations. Three potential scenarios for AD syringe demand are forecasted to reflect the uncertainty in future demand; the forecast indicates adequate supply in all three scenarios.

A reliable supply chain is often referred to as the “backbone” of a health system. In addition to meeting the demand for drugs and medical supplies, it serves to safeguard a country’s investments in health commodities, which is particularly important as countries ramp up efforts to work toward universal health coverage.The aim of this Journey of the Pill assessment is to identify strengths and inefficiencies in the noncommunicable disease (NCD) supply chain in Vietnam. It builds on previous NCD supply chain assessments conducted in Ghana, Kenya, and Senegal. Further defining the journey of medicines will help inform the Ministry of Health and other stakeholders of future actions to strengthen commodity security for NCDs.

Training and competency assessment tool for users of the STANDARD G6PD Test